Supplementary Figure 1 and 2 from Modulation of EZH2 Expression by MEK-ERK or PI3K-AKT Signaling in Lung Cancer Is Dictated by Different KRAS Oncogene Mutations

EZH2 and MEK-ERK and PI3K/AKT signaling pathway expression in lung adenocarcinoma and HBEC cell lines KRAS wild-type and with different amino acid substitutions in codon 12 KRAS mutants and Sensitivity in vitro to AZD6244 and MK2206 was significantly increased in the presence of highly selective EZH2 inhibitor GSK343, EPZ6438 and GSK126 in NSCLC cells expressing mutant KRASG12C and KRASG12D, respectively